Combination Therapy «Metformin + Glimepiride» in Patients with Type 2 Diabetes Mellitus (Molecular Mechanisms for Optimization of the Rehabilitation Effect)

Main Article Content

V.V. Poltorak
N.S. Krasova
M.Yu. Horshunskaia


This review describes the molecular mechanisms of therapeutic action of the combination of oral antidiabetic drugs «metformin + glimepiride», aimed at the correction of both defects, which determine the development of metabolic abnormalities in type 2 diabetes mellitus, namely, relative insulin deficiency and insulin resistance. The combination of metformin with glimepiride is optimal in terms of therapeutic effects on both molecules, which metabolic hypoactivity determines the metabolic state of insulin resistance, respectively, adenosine monophosphate-activated protein kinase and peroxisome proliferator-activated receptor γ. In addition, metformin has unique ability to eliminate the phenomenon of «hyperglycemic memory» by increasing the expression and activity of sirtuin-1. On the other hand, the third generation sulfonylurea glimepiride provides a «gentle» stimulation of the β-cells, which maintains the physiological ratio proinsulin/insulin and slows down the development of the phenomenon of β-cell desensitization to physiological and pharmacological stimuli. Glimepiride retains protective phenomenon of ischemic preconditioning and extends the range of therapeutic effect on the pathophysiological components of insulin resistance due to insulin-mimetic and insulin-sensitizing effect, as well as potentiates the beneficial effects of metformin (particularly, via adiponectin). Above mentioned determinated the achievement of optimized therapeutic efficacy of pharmaceutical combination against the background of decreased side effects (reduced dose of glimepiride, metformin).

Article Details

How to Cite
Poltorak, V., N. Krasova, and M. Horshunskaia. “Combination Therapy «Metformin + Glimepiride» in Patients With Type 2 Diabetes Mellitus (Molecular Mechanisms for Optimization of the Rehabilitation Effect)”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 1.65, Mar. 2015, pp. 87-97, doi:10.22141/2224-0721.1.65.2015.75906.
Literature Review


Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP 4th, Boyd AE 3rd, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268(5209):423-426. doi:10.1126/science.7716547.

Alexanderson E, Alexanderson G, Sierra C. Treatment of endothelial dysfunction with glimepiride + metformin in patients with type 2 diabetes mellitus: evaluation with position emission tomography. Diabetologia 2007;50:S483.

Alssema М, Dekker JM, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality. An 11-year follow-up of the Hoorn Study. Diabetes Care 2005;28(4):860-865. doi: 10.2337/diacare.28.4.860.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl. 1):S64-S71. doi: 10.2337/dc12-s064.

American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(Suppl. 1):S11-S66. doi: 10.2337/dc13-S011.

Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag 2012;8:463-72. doi: 10.2147/HIV.S33194.

Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol 2010;205:97-106. doi: 10.1677/JOE-09-0345.

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-834. doi: 10.1046/j.1464-5491.2001.00582.x.

Cheng K, Andrikopoulos S, Gunton JE. First phase insulin secretion and type 2 diabetes. Curr Mol Med 2013;13:126-139. doi: 10.2174/1566524011307010126.

Cnop M, Ladriere L, Igoillo-Esteve M, Moura RF, Cunha DA. Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction. Diabetes Obes Metab 2010;12(suppl. 2):76-82. doi: 10.1111/j.1463-1326.2010.01279.x.

Cooper MB, Al Majali K, Bailey CJ, Betteridge DJ. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. Clin Endocrinol (Oxf) 2008;68(5):738-46. doi: 10.1111/j.1365-2265.2007.03113.x.

Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 2014;7:241-253. doi: 10.2147/DMSO.S43731.

DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835. doi:10. 1016/j.mcna.2004.04.013.

Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001;17:164-174. doi: 10.1002/dmrr.198.

Duan Y, Zhang R, Zhang M, Sun L, Dong S, Wang G, Zhang J, Zhao Z. Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus. Neural Regen Res 2013;8(25):2379-2388. doi: 10.3969/j.issn.1673-5374.2013.25.009.

Dworacka M, Abramczyk M, Winiarska H, Kuczynski S, Borowska M, Szczawinska K. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Int J Clin Pharmacol Ther 2006;44(1):14-21. PMID: 16425966.

Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, Smith RJ, Smith SR. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab 2011;96(6):1654-63. doi: 10.1210/jc.2011-0585.

Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008;29(1):42-61. doi: 10.1210/er.2007-0015.

El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epige netic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205:2409-2417. doi: 10.1084/jem.20081188.

Eriksson L, Nyström T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis Cardiovasc. Diabetol 2014;13(1):152. doi: 10.1186/s12933-014-0152-5.

Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis. J Mol Endocrinol 2001;27:1-9. doi: 10.1677/jme.0.0270001.

Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning Pharmacol Rev 2007;59:418-458. doi:10.1124/pr.107.06002.

Fonseca V., Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283(13):1695-702. doi:10.1001/jama.283.13.1695.

Forst T., Wahren J. New Tricks by an Old Dog. Exp Diabetes Res 2008;2008:384219. doi: 10.1155/2008/384219.

Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated peceptor γ agonistic activity. J Biol Chem 2005;280(25):23653-23659. doi: 10.1074/jbc.M412113200.

Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992;15(5):666-692. PMID: 1516487.

Grill V, Bjorklund A. Overstimulation and β-cell function. Diabetes 2001;50:S122-S124. doi:10.2337/diabetes.50.2007.S122.

Gruzman A, Babai G, Sasson S. Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 2009;6(1):13-36. doi: 10.1900/RDS.2009.6.13.

Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010;33(3):608-13. doi: 10.2337/dc09-1579.

Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-κB activation in vascular endothelial cells. FEBS Letters 2008;582:1719-1724. doi: 10.1016/j.febslet.2008.04.037.

Holman RR, Paul SK, Bethel MA, David R, Matthews H, Andrew W. Neil 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589. doi: 10.1056/NEJMoa0806470.

Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, Kunisaki M, Imamura M, Yu HY, Etoh T, Yoshikawa H, Aoki T, Hashimoto T, Nawata H. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J 2000;47(6):763-70. doi: 10.1507/endocrj.47.763.

Inoue T, Kootoka N, Morooka T. et al. High molecular adiponесtin as a predictor of longterm clinical outcome in patients with coronary artery disease. Am J Cardiol 2007;100:569-574. doi: 10.1016/j.amjcard.2007.03.062.

International Diabetes Federation. Diabetes Atlas, 5th edition, Brussels, Belgium : International Diabetes Federation, 2011.

International Diabetes Federation. Diabetes Atlas, 6th edition, Brussels, Belgium : International Diabetes Federation, 2013

Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, Katayama S. Glimepiride enhances intrinsic peroxisome proliferatoractivated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Byophys Res Commun 2005;328:484-490. doi: 10.1016/j.bbrc.2004.12.190.

Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287(3):360-72 doi:10.1001/jama.287.3.360.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012;35:1-16. doi:10.2337/dc12-0413.

Jia EZ, Yang ZJ, Zhu TB, Wang IS, Chen B, Cao KJ, Huang J, Ma WZ. Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis. Cardiology 2008;110(2):106-111. doi:10.1159/000110488.

Kahn CR et al. Joslin's diabetes mellitus, 14th edition, Boston, Lippincott Williams & Wilkins, 2006. - 328 p. ISBN 0-7817-2796-0.

Khan BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25. doi: 10.1016/j.cmet.2004.12.003.

Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential Diabetes Metab J 2013;37:315-325. doi: 10.4093/dmj.2013.37.5.315.

Koenig W, Khuseinova N, Baumert J, Meisinger C, Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary disease in apparently healthy middle-aged men: results from the 18-year follow up of a large cohort from southern Germany. J Am Cardiol 2006;48:1369-1377. doi:10.1016/j.jacc.2006.06.053.

Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607-1611. doi:10.2337/diacare.25.9.1607.

Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy 2004;24:606-620. doi: 10.1592/phco.24.6.606.34752.

Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006;53:87-94. doi: 10.2152/jmi.53.87.

Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J 2002;49(3):323-328. doi: 10.1507/endocrj.49.323.

Langenfeld MR, Forst T, Standl E, Strotmann HJ, Lubben G, Pahler S, Kann P, Pfűtzer A. IRIS II Study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther 2004;6(6):836-843. doi:10.1089/dia.2004.6.836.

Lee EJ, Marcy TR. The impact of pioglitazone on bladder cancer and cardiovascular events. Consult Pharm 2014;29(8):555-558. doi: 10.4140/TCP.n.2014.555.

Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88(2):531-7. doi: 10.1210/jc.2002-020904.

Ma P, Xiong W, Liu H, Ma J, Gu B, Wu X. Extrapancreatic roles of glimepiride on osteoblasts from rat mandibular bone in vitro: regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway. Arch Oral Biol 2011;56(4):307-316. doi: 10.1016/j.archoralbio.2010.10.009.

Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combination of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004;20:44-47. doi: 10.1002/dmrr.411.

Marquezine GF, Wajchenberg BL. Molecular activity of insulin and selective insulin resistance. Endocrinologist 2007; 7:351-356. doi: 10.1097/TEN.0b013e31815af5ae.

Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010;123(10):877-884. doi: 10.1016/j.amjmed.2010.02.028.

Mocanu MM, Мaddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide Circulation 2001;103(25);3111-3116. doi: 10.1161/01.CIR.103.25.3111.

Mori RC, Hirabara SM, Hirata AE, Okamoto MM, Machado UF. Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin. Diabetes Obes Metab 2008;10(7):596-600. doi:10.1111/j.1463-1326.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203. doi: 10.2337/dc08-9025.

Nelson LE, Valentine RJ, Cacicedo JM, Gauthier M-S, Ido Y. A novel inverse relationship between metformin-triggered AMPK-SIRT1 si gnaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol 2012;303: C4-C13. doi: 10.1152/ajpcell.00296.2011.

Nyback-Nakell A, Adamson U, Lins PE, Landtedt-Hallin L. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration – A randomised , double-blind, placebo-controlled, cross-over study. Diabetes Res Clin Pract 2014;103;286-291. doi: 10.1016/j.diabres.2013.12.062.

O'Keefe JH, Abuannadi M, Lavie CJ, Bell DSH. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011;86(2):128-138. doi: 10.4065/mcp/2010.0434.

Paneni F, Mochara P, Akhmedov A, Costantino S, Osto E, Volpe M, Lüscher TF, Cosentino F. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res 2012;111:278-289. doi: 10.1161/CIRCRESAHA.112.266593.

Paneni F, Volpe M, Luscher TF, Cosentino F. SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes 2013;62:1800-1807. doi: 10.2337/db12-1648.

Pfűtzer A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004;27(3):682-687. doi:10.2337/diacare.27.3.682.

Pfűtzer A, Kann PH, Pfűtzer AH, Kunt T, Larbig M, Weber MM, Forst T. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab 2004;50(9-10):567-573. PMID:15481632.

Pfűtzer A, Hohberg C, Lubben G, Pahler S, Pfűtzer AH, Kann P, Forst T. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005;37(8):510-515. doi: 10.1055/s-2005-870320.

Pfűtzer A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T. The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2006;8(3):375-384. doi:10.1089/dia.2006.8.375.

Pfűtzer A, Derwahl M, Jacob S, Hohberg C, Blumner E, Lehmann U, Fuchs W, Forst T. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study. Diabetes Technol Ther 2010;12(8):599-604. doi: 10.1089/dia.2010.0019.

Pfutzner A, Forst T. Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol 2011;5(3):784-793. PMC3192645.

Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol 2003;2:33-47. ISSN: 1175-6349.

Purushotham A, Shug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9:327-338. doi: 10.1016/j.cmet.2009.02.006.

Rajendran R, Garva R, Kristic-Demonacos M, Demonacos C. SIRTuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription J Biomed Biotechnol 2011;2011:1-17. doi: 10.1155/2011/368276.

Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice 2007;13(Suppl 1):1-68. doi: 10.4158/EP.13.S1.1.

Roumie CL, Greevy RA, Grijava CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014;311(22):2288-2296. doi: 10.1001/jama.2014.4312.

Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123(7):2764-2772. doi: 10.1172/JCI67227.

Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002;63:1921–1935. doi: 10.1016/S0006-2952(02)00996-6.

Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004;89(12):6048-53. doi: 10.1210/jc.2004-0705.

Srivastva RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res 2012;53(12): 2490-2514. doi: 10.1194/jlr.R025882.

Steinberg, GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009;89(3):1025-1078. doi: 10.1152/physrev.00011.2008.

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR UKPDS Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412. doi: 10.1136/bmj.321.7258.405.

Sugden M.C., Holness M.J. Metformin, metabolic stress, and mitochondria. Focus on “A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells”. Am J Physiol Cell Physiol 2012;303:C1-C3. doi: 10.1152/ajpcell.00090.2012.

Tabak AG, Carstensen M, Witte DR, Brunner EJ, Shipley MJ, Jokela M, Roden M, Kivimaki M, Herder C. Adiponectin trajectories before type 2 diabetes diagnosis. Whitehall II study. Diabetes Care 2012;35:2540-2547. doi: 10.2337/dc11-2263.

Tann M, Miura T, Tsuchida A, Miki T, Nishino Y, Ohnuma Y, Shimamoto K. Contribution of both sarcolemmal K-ATP and mitochondrial K-ATP channels to infarct size limitation by K-ATP channels openers: differences from preconditioning in the role of sarcolemmal K-ATP channels. Naunyn-Schmiedeberg’s Arch Pharmacol 2001;364:226-232. PMID: 11521165.

Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003;26:285-289. doi:10.2337/diacare.26.2.285.

Turner RC, Holman RR. Metformin and risk of cardiovascular disease. Cardiology 1999;91(3):203-4. doi:10.1159/000006910.

Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006;22(4):751-759. doi: 10.1185/030079906X104786.

Van de Vyver M, Andrag E, Cockburn IL, Ferris WF. Thiazolidinedione-induced lipid droplet formation during osteogenic differentiation. J Endocrinol 2014;223(2):119-132. doi: 10.1530/JOE-14-0425.

Wu CZ, Pei D, Hsieh AT, Wang K, Lin JD, Lee LH, Chu YM, Hsiao FC, Pei C, Hsia TL. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. Arch Pharm Res 2010;33:411-416 doi: 10.1007/s12272-010-0310-6.

Xu DY, Zhao SP, Huang QX, Du W, Liu YH, Liu L, Xie XM. Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;88:71-75. doi: 10.1016/j.diabres.2009.12.010.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T.Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295. doi: 10.1038/nm788.

Yunukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, Katayama S. Glimeperide enhaces intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Byophys Res Commun 2005;328:484-490. doi:10.1016/j.bbrc.2004.12.190.

Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou J-P, Ferrieres J, Simon T. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010;95:4993-5002. doi: 10.1210/jc.2010-0449.

Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease. Report from a 27-year follow-up study. Circulation 2002;105:2153-2158. doi: 10.1161/01.CIR.00000015855.04844.E7.

Zhou S, Chen HZ, Wan YZ, Zhang QJ, Wei YS, Huang S, Liu JJ, Lu YB, Zhang ZQ, Yang RF,Zhang R, Cai H, Liu DP, Liang CC. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction Circ Res 2011;109:639-648. doi: 10.1161/CIRCRESAHA.111.243592.

Poltorak VV, Krasova N, Gorshunska M. Sirtuiny kak perspektivnaja mishen' dlja profilaktiki i terapii saharnogo diabeta. Probl. Endokr. Patologii 2014(3):97-104.

Most read articles by the same author(s)

1 2 > >>